Update on the ELIANA trial (VIDEO)

According to data presented at AAAAI, berotralstat demonstrated a well tolerated safety profile and early and sustained reductions in monthly HAE attacks among patients aged 2 to under 12 years.

First approved for PNH in 2007, the monoclonal antibody is now the first and only treatment for pediatric patients living with gMG.

Results will be included an a final analysis of safety and efficacy data for CTx-1301, which will be included in a NDA submission with the FDA, stated Cingulate Inc.

Colleen Sloan, PA-C, RDN, emphasizes the importance of learning to spot added sugars, compare portion sizes, and recognize misleading marketing claims to give patients a practical tool to take ownership of their health.